Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jefferies Financial
JEF
5
Amazon
AMZN
HK Stock MarketDetailed Quotes
09606 DUALITYBIO-B
- 207.400
- -7.000-3.26%
Market Closed Apr 30 16:08 CST
17.72BMarket Cap-15.62P/E (TTM)
218.800High206.800Low237.69KVolume216.000Open214.400Pre Close49.91MTurnover0.28%Turnover RatioLossP/E (Static)85.44MShares234.60052wk High-8.12P/B17.72BFloat Cap178.80052wk Low--Dividend TTM85.44MShs Float234.600Historical High--Dividend LFY5.60%Amplitude178.800Historical Low209.963Avg Price100Lot Size--Div YieldTTM--Div Yield LFY
About DUALITYBIO-B Company
Yingen Biotech is an innovative clinical-stage biopharmaceutical company focused on developing next-generation antibody-conjugated drugs (ADCs) for patients with cancer and autoimmune diseases. The company has successfully built several next-generation ADC technology platforms with global intellectual property rights. Based on in-depth research and exploration of the biological mechanisms of diseases, Yingen Biotech has a rich clinical ADC research and development pipeline, and has carried out multiple global multi-center clinical trials in more than 17 countries, enrolling more than 2,000 patients. At the same time, Yingen Biotech has reached a number of overseas licensing agreements with global pharmaceutical companies and top innovative pharmaceutical companies. As a global ADC innovation engine, Yingen Biotech continues to develop the next generation of novel ADCs, including dual-antibody ADCs, novel mechanism-loaded ADCs, and self-exempt ADCs.
Company Profile
Symbol09606
Company NameDUALITYBIO-B
ISINKYG2929M1087
Listing DateApr 15, 2025
Issue Price94.60
Shares Offered17.33M share(s)
FoundedJul 3, 2019
Registered AddressCayman Islands
Chairmanzhongyuan zhu
Secretaryjialicengyingwen yuan
Audit InstitutionPricewaterhouseCoopers
Company CategoryOverseas registration of Mainland Individuals control
Registered Office4th Floor, Harbour Place 103 South Church Street George Town P.O. Box 10240 Grand Cayman KY1-1002 Cayman Islands
Head Office and Principal Place of Business40th Floor, Dah Sing Finance Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees170
MarketHong Kong motherboard
Phone(021)26018730
EmailIR@dualitybiologics.com;info@dualitybiologics.com
Business Yingen Biotech is an investment holding company mainly engaged in clinical-stage biopharmaceuticals. The company is dedicated to developing innovative antibody-conjugated drugs (ADCs) for patients with cancer and autoimmune diseases. The company's main drug candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419, and DB-2304. The company's products are mainly used to target endometrial cancer (EC), breast cancer (BC), small cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), and head and neck squamous cell carcinoma (HNSCC). The company mainly operates in domestic and foreign markets.
Company Executives
- Name
- Position
- Salary
- zhongyuan zhu
- Chairman of the Board, CEOs, Executive Director, Chairman of the Nomination Committee, Originators, Authorized Representative
- --
- shaoren zhang
- Executive Director, Vice President of Finance
- --
- wen si
- Executive Director, Executive Director of Human Resources, Remuneration Committee Members
- --
- zhiyang cai
- Non-executive Directors
- --
- tao yu
- Non-executive Directors
- --
- QIU Yang
- Chief Scientific Officer
- --
- dong xie
- Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members
- --
- hua mou
- Global Chief Medical Officer
- --
- fengyong gao
- Independent Non-Executive Director, Remuneration Committee Members, Audit Committee Members
- --
- shuyin chuai
- Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
- --
- wei gu
- Chief Medical Officer
- --
- WANG Xin
- Chief Commercial Officer
- --
- haiqing hua
- Senior Vice President, Head of Drug Discovery
- --
- xin yu
- Vice President and Head of Regulatory Affairs
- --
- SHI Rong
- Vice President of Development Sciences
- --
- CHU Ruiyin
- Vice President of Translational Medicine
- --
- lan zhou
- Vice President of Business Strategy
- --
- jiali yuan
- Legal and Compliance Officer, Joint Company Secretary
- --
- yingwen ceng
- Joint Company Secretary, Authorized Representative
- --
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts